Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 9/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25276459 | 0.92 | TLR9 (0.35) | TLR9TLR8TLR7HTR2CKHK | |
| SCHEMBL25235906 | 0.88 | TLR9 (0.38) | TLR9TLR8TLR7KHK | |
| SCHEMBL25232650 | 0.88 | TLR8 (0.39) | TLR9TLR8TLR7HTR2C | |
| SCHEMBL25230660 | 0.86 | HTR2C (0.34) | TLR9TLR8TLR7HTR2CKHK | |
| SCHEMBL25277031 | 0.86 | HTR2C (0.34) | TLR9TLR8TLR7HTR2CKHK | |
| SCHEMBL25407982 | 0.85 | TLR9 (0.40) | TLR9TLR8TLR7L3MBTL1CYP1A2 | |
| SCHEMBL25217674 | 0.82 | TLR8 (0.43) | TLR9TLR8TLR7 | |
| SCHEMBL25408695 | 0.81 | SMO (0.38) | — | |
| SCHEMBL25407585 | 0.80 | TLR9 (0.34) | TLR9TLR8TLR7KHK | |
| SCHEMBL26309352 | 0.80 | L3MBTL1 (0.36) | TLR9TLR8TLR7L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | claimed |
| EP-4192588-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-06-14 | — | — | EP | claimed |
| CN-115835911-A | Imidazo [1,2-a ] pyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-03-21 | — | — | CN | claimed |
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4192588-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-06-14 | — | — | EP | disclosed |
| CN-115835911-A | Imidazo [1,2-a ] pyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, CNKSR1, UACA | TLR9 461/4885TLR8 1464/4885TLR7 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.